Lorcaserin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an [[anorectic]]. On 27 June 2012, the FDA officially approved lorcaserin for use in the treatment of obesity for adults with a BMI equal to or greater than 30 or adults with a BMI of 27 or greater who "have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol". | Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an [[anorectic]]. On 27 June 2012, the [[Food and Drug Administration|FDA]] officially approved lorcaserin for use in the treatment of [[obesity]] for adults with a [[BMI]] equal to or greater than 30 or adults with a BMI of 27 or greater who "have at least one weight-related health condition, such as high [[blood pressure]], [[type 2 diabetes]], or high [[cholesterol]]". | ||
==References== | ==References== | ||
Revision as of 02:30, 28 June 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. On 27 June 2012, the FDA officially approved lorcaserin for use in the treatment of obesity for adults with a BMI equal to or greater than 30 or adults with a BMI of 27 or greater who "have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol".